aGvHD |
Acute graft versus host disease |
ALL |
Acute lymphoblastic leukemia |
ATG |
Anti-thymocyte globulin |
AUC |
Area under the curve |
BM |
Bone marrow |
Bu |
Busulfan |
CAR-T |
Chimeric antigen receptor T-cell |
cGvHD |
Chronic graft versus host disease |
CHC |
Chemotherapy-based conditioning |
CI |
Confidence interval |
CIR |
Cumulative incidences of relapse |
CMV |
Cytomegalovirus |
Cy |
Cyclophosphamide |
EBV |
Epstein Barr Virus |
EFS |
Event free survival |
Flu |
Fludarabine |
FORUM |
For Omitting Radiation Under Majority age |
GvHD |
Graft versus host disease |
HLA |
Human leukocyte antigen |
HSCT |
Hematopoietic stem cell transplantation |
IgG |
Immunoglobulin G |
IQR |
Interquartile range |
IV |
Intravenous |
MRD |
Minimal Residual Disease |
NRM |
Non-relapse mortality |
OS |
Overall survival |
PBSC |
Peripheral blood stem cell |
SOS |
Sinusoidal obstructive syndrome |
TBI |
Total body irradiation |
TDM |
Targeted drug monitoring |
Treo |
Treosulfan |